Search Results
Results found for "Luisa Salter-Cid"
Posts (63)
- GPCR Therapeutics Expands Scientific Advisory Board
Luisa Salter-Cid, Dr. Omar Nadeem and Dr.
- N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 ...
October 2022 N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
In this session, you’ll gain: ✅ A deeper understanding of how every ligand alters receptor conformation—and why this can’t be ignored ✅ Practical examples of how probe dependence alters efficacy, selectivity These changes can alter how the receptor talks to G proteins, arrestins, or other receptors. how cryptic binding pockets —sites that only exist briefly in certain receptor states—can drastically alter In this lecture, Kenakin lays out why no ligand binds without altering receptor conformation , and how
Other Pages (2)
- Ever wondered how we perceive bitterness? 👅🔬 Researchers have unveiled the cryo-EM structure of TAS2R14, the most promiscuous bitter taste receptor, bound to the drug flufenamic acid (FFA) and its signaling partner gustducin! 🌟 This discovery reveals an unusual dual binding mode of FFA and offers tools for site-targeted compound design. 🧪✨ Learn more about this exciting breakthrough in bitter taste signaling. | Dr. GPCR Ecosystem
utm_campaign=5d751e7a-3ecb-4719-8ba3-974d17e9f596&utm_source=so&utm_medium=mail&cid=79a6b35e-7ba6-44a0
- Dr. Yamina Berchiche | Dr. GPCR Ecosystem
Alexander Hauser , and Luise Wagner .
